Table 2: Slide Cost-effectiveness ratios—increasing aspirin use from 55% to 75% of eligible populations.

Baseline scenario	£ per CV event avoided	£ per life year gained
Males
25–34	6,113.66	254.74
35–44	1,045.38	55.02
45–54	5.88	0.42
55–64	−336.42	−37.38
65–74	−487.50	−121.87
75+	−561.75	−2,247.00
Females
25–34	564,259.62	22,570.38
35–44	7,016.45	350.82
45–54	461.45	30.76
55–64	−132.60	−13.26
65–74	−267.73	−53.55
75+	−275.44	−220.36